Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous UCB Mononuclear Cells for CDH
NCT03526588Phase 1Terminated
- Sponsor
- UTHealth Houston
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous umbilical cord blood-derived mononuclear cells in congenital diaphragmatic hernia (CDH), sponsored by UTHealth Houston. Primary endpoints: Safety as assessed by vital sign monitoring (heart rate), Safety as assessed by vital sign monitoring (systolic blood pressure) and 12 more. Started Aug 2018; status: terminated.
02
Drugs
autologous umbilical cord blood-derived mononuclear cells
03
Conditions
congenital diaphragmatic hernia (CDH)
Beyond the preview
Go deeper on NCT03526588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526588.